Skip to main content
Explore URMC

menu

Gastric Cancer: Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Research Question:
Are the drugs pembrolizumab (Keytruda) and trastuzumab safe and effective when given in combination with other chemotherapy drugs in treating patients with HER2-positive gastric cancer?

Basic Study Information

Purpose:
A small number of esophagus cancers have too much of the HER2 protein on the surface of their cells, which can help cancer cells to grow. Having too much of this protein is caused by having too many copies of the HER2 gene. If you have esophageal cancer and can’t have surgery, your doctor may have your tumor biopsy samples tested for the HER2 protein or gene. The study will compare drugs that target HER2-positive cancers.

Location: University of Rochester Medical Center
Study Reference #: IGIE18064

Lead Researcher (Principal Investigator)

Lead Researcher: Mohamedtaki Tejani, MD

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search